Bulletin
Investor Alert

New York Markets After Hours

Topics

Hepatitis

2:13 a.m. July 31, 2020 - By Jaimy Lee
Gilead swings to a big loss on acquisition expense, stock falls after earnings and revenue miss The drugmaker expects to produce more than 2 million courses of COVID-19 treatment remdesivir by the end of the yearShares of Gilead Sciences Inc. fell more than 1% in after-hours trading Thursday after the drugmaker reported that it swung to a large loss during the second quarter and missed estimates even after adjusting for an acquisition.
Browse topics:
Link to MarketWatch's Slice.